AGIOS PHARMACEUTICALS, INC.
Last · —$30.97+0.76 (+2.52%)live · yahoo · 1h ago
Market cap$1.85B—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $98.3M |
|---|---|
| Operating income | $-220.6M |
| Net income | $-199.8M |
| Free cash flow | $-178.2M |
| Operating margin | -224.3% |
| Net margin | -203.2% |
| Return on equity | -19.5% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-12
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 97.3%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -764.0%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -690.3%
- Cash Runway Low — Cash runway ~0.2 years
- Rd Intensity High — R&D/Revenue 628.4%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.22
Est. revenue
51.9M
Press & signals
- GlobeNewswire
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update